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Background: Elevated intraocular pressure (IOP) is a major risk factor for glaucoma, a degenerative disease
characterized by the loss of retinal ganglion cells (RGCs). There is clinical and experimental evidence that
neuroinflammation is involved in the pathogenesis of glaucoma. Since the blockade of adenosine A2A receptor
(A2AR) confers robust neuroprotection and controls microglia reactivity in the brain, we now investigated the ability
of A2AR blockade to control the reactivity of microglia and neuroinflammation as well as RGC loss in retinal
organotypic cultures exposed to elevated hydrostatic pressure (EHP) or lipopolysaccharide (LPS).
Methods: Retinal organotypic cultures were either incubated with LPS (3 μg/mL), to elicit a pro-inflammatory
response, or exposed to EHP (+70 mmHg), to mimic increased IOP, for 4 or 24 h, in the presence or absence of the
A2AR antagonist SCH 58261 (50 nM). A2AR expression, microglial reactivity and neuroinflammatory response were
evaluated by immunohistochemistry, quantitative PCR (qPCR) and enzyme-linked immunosorbent assay (ELISA). RGC
loss was assessed by immunohistochemistry. In order to investigate the contribution of pro-inflammatory mediators
to RGC loss, the organotypic retinal cultures were incubated with rabbit anti-tumour necrosis factor (TNF) (2 μg/mL)
and goat anti-interleukin-1β (IL-1β) (1 μg/mL) antibodies.
Results: We report that the A2AR antagonist (SCH 58261) prevented microglia reactivity, increase in pro-inflammatory
mediators as well as RGC loss upon exposure to either LPS or EHP. Additionally, neutralization of TNF and IL-1β
prevented RGC loss induced by LPS or EHP.
Conclusions: This work demonstrates that A2AR blockade confers neuroprotection to RGCs by controlling
microglia-mediated retinal neuroinflammation and prompts the hypothesis that A2AR antagonists may be a
novel therapeutic option to manage glaucomatous disorders.
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Glaucoma is the third leading cause of visual impair-
ment and the second cause of blindness worldwide [1].
It is defined as a group of chronic degenerative optic
neuropathies, characterized by the irreversible and pro-
gressive loss of retinal ganglion cells (RGCs) and damage
of the optic nerve (RGC axons). Although glaucoma is a* Correspondence: asantiago@fmed.uc.pt
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is a major risk factor and the current treatments are
mainly focused on reducing IOP [2]. However, many
patients continue to lose vision despite the control of
IOP, and neuroprotective strategies aimed to prevent
RGC loss are necessary [3].
Increasing evidence has shown that neuroinflammation
has an important role in the pathogenesis of glaucoma
[4–6]. Accordingly, microglial cells display an activated
amoeboid-like morphology at the early stages of glaucoma
[7–10]. In parallel, there is an increased expression and
release of pro-inflammatory cytokines [e.g. tumour necrosisarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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in the glaucomatous eye [11–14]. The importance of this
microglia-associated neuroinflammation in glaucoma is
underscored by the observation that the control of micro-
glia activation [15–17] or of pro-inflammatory cytokine
expression [4, 18] can prevent the loss of RGC in animal
models of glaucoma.
Microglia-associated neuroinflammation is also involved
in different brain disorders [19]. Adenosine is a neuromo-
dulator, which can control inflammatory reactions [20, 21]
and microglia reactivity [22–24] mainly through the acti-
vation of its G-protein-coupled receptor of the A2A recep-
tor (A2AR) subtype [25]. Accordingly, A2AR antagonists
afford robust neuroprotection upon ischemia, epilepsy or
Alzheimer’s or Parkinson’s disease [25].
All these evidence prompt the hypothesis that A2AR
antagonists may also control the microglia-associated
neuroinflammation and loss of RGC in animal models of
glaucoma. Therefore, the main aim of this work was to
investigate whether A2AR blockade modulates retinal
microglia reactivity, neuroinflammation and loss of RGC




Adult Wistar rats were housed in certified local facilities,
in a temperature- and humidity-controlled environment,
and were provided with standard rodent diet and water
ad libitum, under a 12 h light/12 h dark cycle. All proce-
dures involving animals were approved by the Ethical
Committee of the Faculty of Medicine of the University
of Coimbra/Center for Neuroscience and Cell Biology
and are in agreement with the Association for Research
in Vision and Ophthalmology statement for animal use.
Organotypic retinal cultures
Wistar rats (8–10 weeks old) were euthanized and their
eyes enucleated. Retinas were dissected in a Ca2+- and
Mg2+-free Hank’s balanced salt solution (HBSS (in mM)
137 NaCl, 5.4 KCl, 0.45 KH2PO4, 0.34 Na2HPO4, 4
NaHCO3, 5 glucose; pH 7.4) and placed in tissue culture
inserts (Millipore; 0.4-μm pore diameter) with the gan-
glion cell layer (GCL) facing up. The retinas were
cultured for 4 days in DMEM-F12 with GlutaMAX I,
supplemented with 10 % heat-inactivated foetal bovine
serum and 0.1 % gentamicin (all from Life Technologies)
at 37 °C, in 5 % CO2 humidified atmosphere, as previously
described [26]. The culture medium was replaced at
culture days 1 and 2.
Culture treatments
Organotypic retinal cultures were either incubated with
LPS (3 μg/mL, Sigma-Aldrich) or exposed to EHP (70mmHg above atmospheric pressure) for 4 or 24 h. The
concentration of LPS was chosen amongst three tested
concentrations of LPS (1, 3 and 5 μg/mL), as the lowest
triggering an increase in iNOS immunoreactivity in the
majority of microglial cells in organotypic retinal cultures.
For the EHP experiments, we used a custom-made hu-
midified pressure chamber equipped with a pressure gauge
and a pressure regulator, which allowed maintaining a
constant pressure with an air mixture of 95 % air and 5 %
CO2, as described previously [27]. The chamber was
placed in an oven at 37 °C. The magnitude of pressure
elevation (70 mmHg above atmospheric pressure) was
chosen in accordance with previous studies [27, 28]. For
ambient pressure experiments, the organotypic retinal
cultures were kept in a standard 5 % CO2 humidified
incubator.
The cultures were incubated with a selective A2AR
antagonist (SCH 58261; Tocris Bioscience), tested at a
selective and supra-maximal concentration (50 nM) [24],
which was added 45 min before exposure to LPS or EHP.
To test the role of extracellular adenosine, organotypic
cultures were treated with 1 U/mL adenosine deaminase
(ADA; Roche Applied Science) which catalyzes the irre-
versible deamination of adenosine to inosine. In order to
investigate the contribution of pro-inflammatory media-
tors to RGC loss, the organotypic retinal cultures were in-
cubated with rabbit anti-TNF (2 μg/mL; Peprotech) and
goat anti-IL-1β (1 μg/mL; R&D Systems) antibodies, or
with corresponding immunoglobulin Gs (IgGs), 45 min
before exposure to LPS or EHP for 24 h. Organotypic cul-
tures were also incubated with 20 ng/mL TNF and 10 ng/
mL IL-1β (ImmunoTools) to evaluate if TNF and IL-1β,
by themselves, lead to RGC loss.
Immunohistochemistry
Organotypic cultures were washed with phosphate-buffered
saline (PBS (in mM) 137 NaCl, 2.7 KCl, 10 Na2HPO4
and 1.8 KH2PO4; pH 7.4) and fixed with ice-cold ethanol
for 10 min at 4 °C. After washing in PBS, cultures were
blocked and permeabilized with 10 % normal goat serum,
3 % bovine serum albumin and 0.1 % Triton X-100 in
PBS, for 1 h, and then incubated with the primary anti-
body (Table 1) for 48 h at 4 °C. After washing, cultures
were incubated overnight with the secondary antibody
(Table 1), at 4 °C. Retina cultures were then washed and
incubated with 4′,6-diamidino-2-phenylindole (DAPI;
1:1000) for 15 min, to stain nuclei. After washing, the
preparations were flat-mounted on slides and cover-
slipped using Glycergel mounting medium.
Image acquisition and densitometric analysis
The preparations were observed with a confocal micro-
scope (LSM 710, Zeiss) on an Axio Observer Z1 micro-
scope using an EC Plan-Neofluar 40x/1.30 Oil DIC M27




Anti-A2AR Santa Cruz Biotechnology Goat 1:100
Anti-CD11b AbD Serotec Mouse 1:250
Anti-iNOS BD Biosciences Rabbit 1:200
Anti-Brn3a Chemicon Mouse 1:500
Secondary antibodies
Alexa Fluor anti-mouse 568 Life Technologies Donkey 1:200
Alexa Fluor anti-goat 488 Life Technologies Rabbit 1:200
Alexa Fluor anti-rabbit 488 Life Technologies Goat 1:200
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of the GCL were randomly acquired (encompassing cen-
tral and peripheral retina), in a total of 12 images. The
settings and exposure times were kept identical for all
conditions within each experiment. Densitometric ana-
lysis was performed using the public domain ImageJ
program (http://rsb.info.nih.gov/ij/). Corrected total cell
fluorescence (CTCF) was calculated as previously de-
scribed [29] using the following formula:
CTCF ¼ Integrated density−ðarea of selected cell
mean fluorescence of background readingÞ
Circularity index and skeleton analysis
Morphological alterations of microglia were estimated as
previously described [30] using the confocal images of the
retinal organotypic cultures labelled with anti-CD11b.
Briefly, the particle measurement feature of ImageJ was
used to automatically evaluate the circularity index (CI) of
microglia, using the formula CI = 4π(area/perimeter2). A
circularity index of 1.0 indicates a perfect circle.
The microglial cell complexity and branch length were
assessed by skeleton analysis using ImageJ software, as de-
scribed previously [31]. Briefly, confocal images were con-
verted to 8-bit format, followed by noise de-speckling to
eliminate single-pixel background fluorescence. Then, im-
ages were converted to binary images, which were analyzed
using AnalyzeSkeleton plugin (http://fiji.sc/AnalyzeSkele-
ton) to assess the number of microglial cell processes, num-
ber of branch endpoints and maximum branch length for
each cell. These results were analyzed as average per frame.
ATP quantification
The extracellular levels of adenosine triphosphate (ATP)
were quantified with a luciferase ATP bioluminescence
assay kit (Sigma-Aldrich) as we previously described
[32]. Briefly, the supernatants were collected and imme-
diately stored at −80 °C until used. Then, 80 μL of thesesupernatant were added to a white 96-well plate (de-
signed for bioluminescence) placed in a VICTOR multi-
label plate reader (PerkinElmer). The luciferin-luciferase
ATP assay mix (40 μL) was automatically loaded in each
well, and the luminescence output was converted to
ATP concentration by interpolation of a standard curve,
which was linear between 2 × 10−12 and 8 × 10−5 M.
ATP concentration was normalized to the total amount
of protein of each retina, which was determined by the
bicinchoninic acid assay (Pierce Biotechnology).
NO production assay
The production of NO was quantified by the Griess reac-
tion method in the supernatants of the culture medium.
The culture medium was centrifuged (10,000g for 10 min)
and the supernatant stored at −80 °C until use. Then,
the supernatant was incubated (1:1) with Griess reagent
mixture (1 % sulfanilamide in 5 % phosphoric acid with
0.1 % N-1-naphthylethylenediamine) for 30 min at room
temperature and in the dark. The optical density was
measured at 550 nm using a microplate reader (Synergy
HT; Biotek). The nitrite concentration was determined
from a sodium nitrite standard curve.
Quantitative real-time PCR
Total RNA was extracted using Qiagen RNeasy Mini Kit
(Qiagen), according to the instructions provided by the
manufacturer. The concentration and purity of total RNA
were determined using NanoDrop ND1000 (Thermo Sci-
entifics). Then, 1 μg of total RNA was reversed transcribed
using a NZY First-Strand cDNA Synthesis Kit according
to the manufacturer instructions (NZYTech, Portugal).
The resultant complementary DNA (cDNA) was treated
with RNase-H for 20 min at 37 °C, and a 1:2 dilution was
prepared for quantitative PCR (qPCR) analysis. All cDNA
samples were stored at −20 °C until further analysis.
Genomic DNA contamination was assessed with a
conventional PCR for β-actin using intron-spanning
primers (Table 2), as described previously [33]. SYBR
Green-based real-time qPCR was performed using a Ste-
pOnePlus PCR system (Applied Biosystems). The PCR
conditions were as follows: iTaq™ Universal SYBR® Green
Supermix (Bio-Rad), 200 nM primers (Table 2) and 2 μL
of 1:2 dilution of cDNA, in a total volume of 20 μL.
Cycling conditions were a melting step at 95 °C for 15 s,
annealing elongation at 60 °C for 45 s and extension at
72 °C, with 40 cycles. A dissociation curve at the end of
the PCR run was performed by ramping the temperature
of the sample from 60 to 95 °C, while continuously col-
lecting fluorescence data. Ct values were converted to
relative quantification using the 2−ΔΔCt method [34].
Three candidate housekeeping genes (hprt, Ywhaz and
GAPDH) were evaluated using NormFinder, a Microsoft
Excel Add-in [35], and hprt was the most stable gene
Table 2 Primers used in qPCR and RT-PCR
Gene GenBank number Forward Reverse Amplicon size (bp)
Adora2A NM_053294 5′ - GGCTATCTCTGACCAACA - 3′ 3′ - TGGCTTGACATCTCTAATCT - 5′ 106
TNF NM_012675 5′ - CCCAATCTGTGTCCTTCT - 3′ 3′ - TTCTGAGCATCGTAGTTGT - 5′ 90
IL-1β NM_031512 5′ - ATAGAAGTCAAGACCAAAGTG - 3′ 3′ - GACCATTGCTGTTTCCTAG - 5′ 109
Nos II NM_012611 5′ - AGAGACAGAAGTGCGATC - 3′ 3′ - AGAGATTCAGTAGTCCACAATA - 5′ 96
hprt NM_012583 5′ - ATGGGAGGCCATCACATTGT- 3′ 3′ - ATGTAATCCAGCAGGTCAGCAA - 5′ 76
actb NM_031144 5′ - GCTCCTCCTGAGCGCAAG - 3′ 3′ - CATCTGCTGGAAGGTGGACA - 5′ 75
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therefore, was used as the housekeeping gene.
Enzyme-linked immunosorbent assay
Culture media was centrifuged (10,000g for 10 min) and
the supernatant was collected and stored at −80 °C until
use. The levels of TNF and IL-1β in the culture superna-
tants were quantified by enzyme-linked immunosorbent
assay (ELISA), according to the instructions provided by
the manufacturer (Peprotech).
Retinal ganglion cell counting
Retinal ganglion cells were identified by immunohisto-
chemistry staining with an antibody anti-Brn3a (RGC
marker), and confocal images of the GCL were acquired (as
described above). The number of Brn3a-immunoreactive
cells per image was counted using ImageJ Cell Counter plu-
gin (http://rsbweb.nih.gov/ij/plugins/cell-counter.html). Re-
sults represent the average of Brn3a-immunoreactive cells
per image.
Statistical analysis
The results are presented as mean ± standard error of
the mean (SEM). The data were analyzed using the non-
parametric Kruskal-Wallis test, followed by Dunn’s mul-
tiple comparison test, as indicated in the figure legends.
The statistical analysis was performed using the Prism
6.0 software for Mac OS X (GraphPad Software, Inc).
Results
The retinal organotypic culture is particularly useful to
evaluate molecular and cellular mechanisms in the retina
because the retinal structure is maintained [26]. Thus,
we used this experimental model to investigate the ability
of A2AR to control neuroinflammation and RGC death
triggered by LPS or EHP (to mimic an increase in IOP).
LPS and EHP increased the expression of A2AR in retinal
microglial cells in the GCL
Since the A2AR modulation system undergoes a gain of
function upon noxious brain conditions [25], we first
assessed if this also occurred in the retina. Therefore, we
investigated if LPS or EHP up-regulated the expression of
A2AR and bolstered the source of adenosine responsiblefor the activation of A2AR, i.e. ATP-derived adeno-
sine [36].
LPS or EHP exposure for 4 h significantly increased
A2AR messenger RNA (mRNA) expression in the retina
by 5.3- and 6.0-fold (n = 6–10), respectively (Fig. 1a).
Accordingly, 4 h after exposure to LPS or EHP, A2AR
immunoreactivity increased mainly in CD11b-positive
cells in the GCL (Fig. 1b), indicating that A2AR in the
GCL are mainly present in microglia.
Extracellular ATP levels in control conditions were 0.6
± 0.3 pmol/μg protein (n = 8) and significantly increased
by 173.8 ± 30 and 215.1 ± 40 % after 24 h of exposure to
LPS or EHP (n = 6–8), respectively (Fig. 1c).
A2AR blockade prevented the alterations of microglia
morphology triggered by LPS or EHP
Modification of cell morphology is one of the hallmarks
of microglia activation and has been widely used to
categorize different activation states [19]. As shown in
Fig. 2a, under control conditions, microglial cells (i.e.
CD11b-positive cells) in the GCL typically presented a
ramified morphology [circularity index (CI) 0.110 ± 0.02,
n = 7; Fig. 2b], compatible with a surveying phenotype.
After 24 h of exposure to LPS or EHP, microglia morph-
ology changed to a more amoeboid-like morphology (CI
0.242 ± 0.014 and 0.182 ± 0.006, respectively; n = 5–8,
P < 0.05 vs. control). Incubation with the selective an-
tagonist of A2AR (SCH 58261, 50 nM) prevented the
LPS- and EHP-induced alterations of microglia circularity
index (n = 5–8) (Fig. 2b). In addition, skeleton morpho-
logical analysis was used to further document more subtle
morphological changes compatible with microglial acti-
vation. Retinal microglia from LPS- and EHP-treated
cultures presented a decrease in the number of branches
(Fig. 2c), endpoints (Fig. 2d) and maximum branch length
(Fig. 2e) compared to the control condition. The blockade
of A2AR prevented these alterations, indicating that
A2AR blockade blunted LPS- and EHP-induced micro-
glia reactivity.
Blockade of A2AR prevented microglia production of NO
Since the activation of microglial cells leads to the pro-
duction of pro-inflammatory and cytotoxic factors like
NO both in vivo and in vitro [37], we tested if A2AR
Fig. 1 LPS or EHP increases A2AR expression and density in retinal microglia and increase the extracellular ATP levels. Retinal organotypic cultures
were challenged with LPS (3 μg/mL) or EHP (+70 mmHg) for 24 h. a A2AR mRNA expression was assayed by qPCR. Results are presented as fold
change of the control, from six to ten independent experiments. b Organotypic retinal cultures were immunostained for A2AR (grey/green; arrowheads)
and CD11b (microglia marker; red) and imaged in the GCL using a confocal microscope. Nuclei were stained with DAPI (blue). Representative images
obtained from four independent experiments. c The extracellular levels of ATP in the medium were quantified by luciferin-luciferase ATP-dependent
reaction. Results are expressed as percentage of control and are mean ± SEM of six to eight independent experiments. **P < 0.01, different from
control; Kruskal-Wallis test, followed by Dunn’s multiple comparison test
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synthase (iNOS), which plays a critical role in neuroin-
flammation by generating high amounts of NO in reactive
microglia [38].
As expected, the mRNA expression of iNOS signifi-
cantly increased by 30.5-fold after 4 h of exposure to LPS
(n = 6), and this effect was significantly decreased upon
A2AR blockade (n = 4) (Fig. 3a). The exposure to EHP for
4 h also significantly increased iNOS mRNA expression
by 4.6-fold over control (n = 5), and the blockade of A2AR
also significantly prevented this effect (n = 6) (Fig. 3a).
In control conditions, the immunoreactivity of iNOS was
barely detected in microglia localized in the GCL (Fig. 3b).
Exposure to LPS or EHP for 24 h significantly increased
iNOS immunoreactivity mainly in CD11b-immunoreactive
cells (Fig. 3b, c), confirming that microglial cells are the
main producers of NO under these conditions. This effect
was abolished by blockade of A2AR, since iNOS immunore-
activity was similar to control (Fig. 3b, c).
The release of NO was indirectly quantified in the culture
medium by Griess reaction 24 h after exposure to LPS orEHP (Fig. 3d). In control conditions, nitrite concentration
was 5.64 ± 0.17 μM (n = 6). LPS or EHP significantly in-
creased nitrite concentration to 149.5 ± 11 and 138 ± 3.5 %
of the control, respectively (n = 4–5), and these effects were
prevented by A2AR blockade (n = 3–4) (Fig. 3d).
A2AR blockade mitigated the inflammatory response
induced by LPS or EHP
Activation of microglia leads to an increased expression
and release of pro-inflammatory cytokines, such as IL-1β
and TNF [19]. To further test if A2AR blockade prevented
the LPS- and EHP-induced inflammatory response, we
quantified mRNA levels encoding for IL-1β and TNF by
qPCR. As shown in Fig. 4a, the exposure of retinal organo-
typic cultures to LPS or EHP for 4 h significantly increased
the transcript levels of IL-1β and TNF (n = 5). Overall, the
blockade of A2AR inhibited the LPS- and EHP-induced in-
crease of IL-1β and TNF mRNA levels (n = 5–7) (Fig. 4a).
We next quantified the levels of IL-1β and TNF in
the culture medium by ELISA (Fig. 4b). In control con-
ditions, the concentration of IL-1β in the culture
Fig. 2 Blockade of A2AR prevents microglia morphological changes induced by LPS or EHP. Retinal organotypic cultures were pretreated with the
A2AR antagonist SCH 58261 (50 nM) and then challenged with LPS (3 μg/mL) or EHP (+70 mmHg) for 4 h. a Organotypic retinal cultures were
immunostained for CD11b (microglia marker; red) and imaged in the GCL using a confocal microscope. Nuclei were stained with DAPI (blue).
Representative images obtained from four to five independent experiments. b the circularity index, c number of branches per cell, d number of process
endpoints per cell and e the maximum branch length (μm) per cell were calculated for the different experimental conditions. The bar graphs present
data as mean ± SEM of four to five independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001, different from control; ++P < 0.01 and +++P < 0.001,
different from LPS; #P < 0.05 and ##P < 0.01, different from EHP; Kruskal-Wallis test, followed by Dunn’s multiple comparison test
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of TNF was 30.9 ± 53.7 pg/mL (n = 10–15). Incubation
with LPS or EHP for 4 h significantly increased IL-1β
concentration in the culture medium to 135.3 ± 6.9
and 146.7 ± 9 pg/mL, respectively (n = 6–8), and the
TNF concentration to 317.6 ± 40.6 and 162.8 ± 42.6
pg/mL, respectively (n = 6–9) (Fig. 4b). The blockade
of A2AR significantly inhibited the LPS- and the EHP-induced increase of IL-1β or TNF levels in the culture
medium (n = 5) (Fig. 4b).
Additionally, we tested if the removal of endogenous
extracellular adenosine was equivalent to blocking A2AR
in the control of LPS- or EHP-induced neuroinflamma-
tion. We found that the pretreatment of organotypic cul-
tures with ADA (1 U/mL), which removes extracellular
adenosine, abrogated the LPS- and EHP-induced increase
Fig. 3 Blockade of A2AR decreases the expression and immunoreactivity of iNOS and NO production induced by LPS or EHP. Retinal organotypic
cultures were pretreated with SCH 58261 (50 nM) and then challenged with LPS (3 μg/mL) or EHP (+70 mmHg) for 4 h. a iNOS mRNA expression
was assessed by qPCR. Results are presented as fold change of the control, from six to twelve independent experiments. b Organotypic retinal
cultures were immunostained for iNOS (green) and CD11b (microglia marker; red) and imaged in the GCL using a confocal microscope. Nuclei were
stained with DAPI (blue). The images are representative of four to five independent experiments. c The immunoreactivity of iNOS in microglia localized
in the GCL was quantified. Results are expressed as percentage of control from four to five independent experiments. d The production of NO was
assessed by the Griess reaction in the culture supernatants, and nitrite formation was quantified. Results are expressed as percentage of control and
are mean ± SEM of four to six independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001, different from control; +P < 0.05, different from
LPS; #P < 0.05 and ### P < 0.001, different from EHP; Kruskal-Wallis test, followed by Dunn’s multiple comparison test
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of both TNF and IL-1β (n = 3).
A2AR blockade prevented RGC death through the control of
neuroinflammation
The elevation of the hydrostatic pressure is an experimen-
tal strategy to mimic in a retina culture model a situation
of IOP increase, which is a major risk factor for glaucoma[2]. Studies from Sappington et al. [27] have already
described RGC death under EHP conditions.
Since A2AR blockade prevented microglia activation
and the expression and release of pro-inflammatory cy-
tokines, we next tested if A2AR blockade also prevented
the loss of RGC induced by LPS or EHP in retinal orga-
notypic cultures. Loss of RGCs was evaluated by count-
ing the number of RGC, identified with an antibody
Fig. 4 A2AR blockade partially inhibits the inflammatory response
induced by LPS or EHP. Retinal organotypic cultures were pretreated
with SCH 58261 (50 nM) and then challenged with LPS (3 μg/mL) or
EHP (+70 mmHg) for 4 h. a Effects of A2AR blockade in the LPS- or
EHP-induced mRNA expression of pro-inflammatory cytokines IL-1β
and TNF were assessed by qPCR. Results are presented as fold
change of the control, from six to thirteen independent experiments.
b The release of IL-1β and TNF to the culture medium was quantified
by ELISA. To evaluate the role of endogenous adenosine, the cultures
were pretreated with adenosine deaminase (ADA; 1 U/mL). Results are
expressed in picogrammes per milliliter and are mean ± SEM of
five to ten independent experiments. **P < 0.01, ***P < 0.001 and
****P < 0.0001, different from control; +P < 0.05, and ++P < 0.01,
different from LPS; #P < 0.05 and ##P < 0.01, different from EHP;
Kruskal-Wallis test, followed by Dunn’s multiple comparison test
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number of Brn3a-immunoreactive cells (Fig. 5a, c)
significantly decreased when the retinal explants were
exposed to LPS or EHP for 24 h, when compared with
the control (190.5 ± 12 Brn3a-immunoreactive cells per
field in control vs. 118.9 ± 11 and 113.9 ± 6 Brn3a-
immunoreactive cells per field in LPS and EHP condi-
tions, respectively, n = 6–7), indicating that both insults
cause RGC loss. This effect was prevented with the
treatment with A2AR antagonist (191.2 ± 7.3 and 184.3 ±
9.3 cells per field, respectively; Fig. 5a, c; n = 4–5).
Since A2AR blockade prevented both inflammatory
responses and RGC loss triggered by LPS and EHP, we
next investigated if TNF and IL-1β were necessary and suf-
ficient to induce RGC loss under noxious conditions (LPS
or EHP). Organotypic retinal cultures were pretreated withantibodies against TNF and IL-1β before incubation with
LPS or exposure to EHP, in order to reduce the levels of
both pro-inflammatory cytokines. The incubation of orga-
notypic retinal cultures with antibodies against TNF and
IL-1β prior incubation with LPS or exposure to EHP fully
prevented the loss of RGCs (180.6 ± 8 and 170.2 ± 4
Brn3a-immunoreactive cells, respectively, n = 5; Fig. 5b, c).
As a control, the incubation with rabbit and goat IgGs did
not significantly inhibit the decrease in the number of
RGC upon exposure to LPS or EHP (n = 4). In addition,
incubation with TNF (20 ng/mL) plus IL-1β (10 ng/mL)
was sufficient to induce loss of RGC (n = 3) (Fig. 5c) to an
extent similar to that triggered by LPS or EHP. Moreover,
incubation with the neutralizing antibodies in control con-
ditions did not alter the number of RGCs present in the
culture (data not shown). The neutralizing experiments
under noxious conditions (LPS or EHP) fully recapitulated
the incubation with SCH 58261, further supporting our
conclusion that A2AR blockade control RGC loss through
a control of retinal neuroinflammation.
Discussion
The present work demonstrates that the blockade of
A2AR prevented retinal neuroinflammation and death of
RGC in an ex vivo model of glaucoma. We exposed ret-
inal organotypic cultures to LPS and EHP, which bol-
stered microglia reactivity, increased neuroinflammatory
response and loss of RGCs. These two noxious condi-
tions up-regulated the A2AR system, as typified by an in-
crease in the extracellular levels of ATP and increased
expression and density of A2AR in microglia. Concomi-
tantly, the A2AR system critically contributed to the neu-
roinflammation and RGC death, since A2AR blockade
prevented the activation of microglia, the production of
pro-inflammatory cytokines and the death of RGCs.
We took advantage of retinal organotypic cultures, a
suitable model to evaluate cellular and molecular signal-
ling mechanisms in which retinal anatomy is maintained
[26] and which has been established as a convenient
model for screening potential neuroprotective drugs in
the retina [41]. This in vitro system enabled us to dem-
onstrate that EHP changed microglia morphology to-
wards an amoeboid-like form, similar to that caused by
LPS, which has been extensively used as a microglial ac-
tivator. Activation of microglial cells is observed as an
early event in animal models of glaucoma [9, 42], in
which increased IOP is a main risk factor [2]. In retinal
organotypic cultures, the observed EHP- and LPS-induced
microglia reactivity was paralleled by an increased expres-
sion and release of the pro-inflammatory cytokines IL-1β
and TNF. Likewise, an increased production of TNF [11,
43] and IL-1β [44, 45] has been observed in glaucomatous
animal models and in human glaucoma. Furthermore, the
ability of anti-IL-1β and anti-TNF antibodies to prevent
Fig. 5 Blockade of A2AR and of TNF and IL-1 β prevents RGC death induced by LPS or EHP. Retinal organotypic cultures were pretreated with
SCH 58261 (50 nM) or with anti-TNF and anti-IL-1β neutralizing antibodies and then challenged with LPS (3 μg/mL) or EHP (+70 mmHg) for 24 h.
Rabbit and goat IgGs were used as control for the neutralization experiments. a Organotypic retinal cultures were immunostained for Brn3a (RGC
marker, red) after treatment with SCH 58261 prior to challenge. Nuclei were stained with DAPI (blue). b Immunostaining with Brn3a (red) after
treatment with neutralizing antibodies prior to challenge. Nuclei were stained with DAPI (blue). Representative images are depicted. c Surviving
RGCs are presented as the number of Brn3a-immunoreactive cells per field and are mean ± SEM of five to seven independent experiments. *P < 0.05
and **P < 0.01, different from control; +P < 0.01 and ++P < 0.01, different from LPS; #P < 0.05 and ##P < 0.01, different from EHP; Kruskal-Wallis
test, followed by Dunn’s multiple comparison test
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the death of RGCs upon exposure to EHP or LPS in ret-
inal organotypic cultures actually resulted from the impact
of pro-inflammatory cytokines. This is in agreement with
previous reports demonstrating that the control of micro-
glia reactivity [15–17] or of pro-inflammatory cytokines
[4, 18, 46] prevents the loss of RGC in animal models of
glaucoma. Nevertheless, the release of IL-6 by astrocytes
and microglia triggered by EHP was reported to protect
RGCs [27], although the authors used purified cultures of
microglia, astrocytes and RGCs and did not evaluate the
possible interactions between these cells in a more com-
plex in vitro model, as the retinal organotypic culture. The
globally deleterious role of microglia-associated pro-
inflammatory status is further heralded by the report thatminocycline, an inhibitor of microglia activation, reduced
microglia activation and improved RGC axonal transport
and integrity [15]. Overall, this evidence indicates that
microglia reactivity is a precocious event and contributes
to the pathophysiology of glaucoma by impairing the
viability of RGCs.
The main conclusion of this study was the critical role
of A2AR in the control of EHP- or LPS-induced micro-
glia activation, production of pro-inflammatory cyto-
kines and RGC death in retinal organotypic cultures.
Indeed, we observed that the blockade of A2AR pre-
vented the EHP- or LPS-induced modification of the
production of pro-inflammatory cytokines and of NO as
it was previously observed in the rodent hippocampus
[24]. Accordingly, it was already demonstrated that
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microglia in culture, an effect that was associated with
microglia neurotoxicity, and A2AR antagonist was sug-
gested as a potential neuroprotective drug [22]. Moreover,
we observed that A2AR blockade prevents EHP-induced
microglia morphological alterations, in agreement with re-
cent findings that A2AR antagonism reduces the retraction
of processes in LPS-activated microglia [47].
These conclusions seems to contradict previous stud-
ies reporting that the activation of A2AR reduces micro-
glia reactivity using primary retinal microglia cultures
exposed either to LPS, hypoxia or amadori-glycated al-
bumin [48–50]. Several factors may explain this discrep-
ancy: (1) while others used cultures of microglial cells,
we used an organotypic retinal culture in which all ret-
inal cells are present, and thus, an additional contribu-
tion from other glial cells cannot be excluded [51, 52];
this is particularly important given that the control by
A2AR of microglia reactivity can be shifted from inhibi-
tory to excitatory by the presence of increased extracel-
lular levels of glutamate [53]; (2) the insults triggering
microglia activation are different and the LPS concentra-
tions and time points were different; and (3) CGS 21680,
the A2AR agonist, at the concentration used in those
studies (20 and 40 μM) is no longer selective, being pro-
posed to bind also to A1R [54, 55]. The A1R is coupled
to Gi/o-proteins and often inhibitory, whereas the A2AR
is usually coupled to Gs-proteins, enhancing cAMP ac-
cumulation and PKA activity [56]. Nevertheless, the
observation of different responses in different models
should be taken into account due to the dual role of
adenosine receptors and different responses of microglia,
which can be elicited with different stimuli and environ-
mental conditions [57]. In fact, in the brain, it is the
blockade rather than the activation of A2AR than reduce
microglia activation and neuroinflammation upon differ-
ent noxious stimuli [58, 24]. This probably contributes
to the neuroprotection afforded by A2AR antagonists in
brain diseases with a neuroinflammatory involvement
such as ischemia, epilepsy, traumatic brain injury, multiple
sclerosis or Alzheimer’s or Parkinson’s disease (reviewed
in [25]). Accordingly, we also observed that A2AR block-
ade prevented the LPS- and the EHP-induced RGC death
in retina organotypic cultures. This might result from the
ability of A2AR to control the activation of microglia and
the production of pro-inflammatory cytokines that we
showed to be sufficient and necessary to trigger RGC
death, but it may also involve an ability of A2AR to directly
control neuronal viability. In fact, neuronal A2AR can
directly affect the degeneration of mature neurons upon
exposure to different stimuli (e.g. [59, 60]), namely to
pro-inflammatory cytokines [61], whereas they have an
opposite effect in immature neurons [62, 63] and during
neurodevelopment [64].In our work, the relevance of the A2AR modulation
system in the control of RGC death through a control of
neuroinflammation in the retina is further underscored
by the observed up-regulation of this system in retinal
organotypic cultures exposed either to LPS or to EHP.
In fact, LPS and EHP caused an increase in the extracel-
lular levels of ATP. The cellular source of this extracellu-
lar ATP is not clear, but it can be released from different
cells in the retina, such as RGCs [65], microglia [66] and
Müller cells [67]. Moreover, recent work demonstrated
that astrocytes present in the optic nerve head can also
release ATP through pannexin channels in response to a
mechanical strain, suggesting this mechanism as a
source of extracellular ATP under chronic mechanical
strain, as occurs in glaucoma [68]. Actually, elevated
levels of extracellular ATP have been reported in the ret-
ina as a response to an acute rise in ocular pressure [69,
70], and the ATP levels are elevated in the aqueous
humour of patients with primary acute and chronic
angle closure glaucoma, which presents evidence for a
contribution of the purinergic signaling in this disease
[71, 72]. The increased levels of ATP can function as a
danger signal [73] and can either activate P2 receptors,
namely P2X7 receptors in the retina [74, 65, 75, 76], or
be extracellular catabolized by ecto-nucleotidases into
extracellular adenosine that preferentially activates A2AR
[77, 36]. Remarkably, EHP and LPS not only bolstered
the source of adenosine activating A2AR but also trig-
gered an increased expression of A2AR, which was trans-
lated into an increased density of A2AR in microglia.
This is in accordance with the up-regulation of A2AR
that is observed upon different noxious conditions
(reviewed in [78, 25]), namely in microglia [79, 24, 80].
Thus, noxious stimuli such as LPS or EHP triggered an
up-regulation of the A2AR system in retinal microglia,
which critically contributes to the development of neu-
roinflammation and RGC death. We cannot rule out the
role of A2AR present in other cell types of the retinal
organotypic culture, but in the GCL, A2AR was found to
be mainly located in microglia. Furthermore, additional
studies will be required to determine if A2AR blockade
only affords a prophylactic benefit or may also be thera-
peutically effective.
Conclusions
The present results demonstrate that EHP can lead to an
inflammatory response, similar to LPS, which is associ-
ated with the death of RGC. Thus, the organotypic
retinal culture exposed to EHP may be an important ex-
perimental model to investigate neuroprotective and
anti-inflammatory pharmacological strategies against
RGC death. Herein, we demonstrate for the first time
that A2AR blockade prevents retinal microglia reactivity
and pro-inflammatory responses triggered by LPS or
Madeira et al. Journal of Neuroinflammation  (2015) 12:115 Page 11 of 13EHP and confers neuroprotection to RGC by controlling
retinal neuroinflammation induced by EHP or LPS. This
prompts the hypothesis that A2AR antagonists might
have therapeutic potential in the treatment of glaucoma,
a proposal re-enforced by the report that IOP could be
reduced by a selective A2AR antagonist, ZM 241385, in
mice [81].
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